Tuberculosis is one of the deadliest infectious diseases on the planet, killing more people each year than HIV or malaria. What makes TB especially destructive is the range of damage it inflicts: it can hollow out lung tissue, spread to the spine and brain, leave lasting disability even after a cure, and financially devastate families caught in months of treatment. The bacterium behind it, Mycobacterium tuberculosis, has been co-evolving with humans for tens of thousands of years, and it has gotten very good at exploiting our biology. Understanding what TB actually does to a person, stage by stage, reveals why it remains such a formidable global health threat.
What Happens Inside You After Exposure
TB spreads through the air when someone with active disease breathes, speaks, or coughs. The infectious particles are tiny, generated deep in the lungs through a mechanism in the small airways where fluid films stretch and burst during normal breathing, launching droplets small enough to stay airborne for hours.1PubMed Central. Is cough really necessary for TB transmission? This means you don’t necessarily need to be coughed on directly. Simply sharing poorly ventilated indoor air with an infectious person can be enough. Research on classroom settings has shown that ventilation rates of at least five to six air changes per hour are needed to bring the risk of TB transmission to acceptable levels, roughly half what is recommended for healthcare facilities.2PLOS ONE. Shared Air: A Renewed Focus on Ventilation for the Prevention of Tuberculosis Transmission
Once inhaled, TB bacteria settle in the lungs and are swallowed by immune cells called macrophages, which are supposed to destroy invaders. TB has evolved ways to survive inside these very cells, essentially using the body’s first line of defense as a hiding place. If the immune system responds strongly enough, it walls the bacteria off inside dense clusters of immune cells known as granulomas. Research in animal models has shown that this encapsulation involves an initial burst of immune activity followed by fibrosis around the granuloma, physically sealing the bacteria in and limiting the spread of new lesions.3PubMed Central. Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs
For most people who are exposed, the story pauses here. Roughly a quarter of the world’s population carries a latent TB infection, meaning the bacteria persist in a contained, dormant-like state with no symptoms and no ability to spread the disease. But “latent” doesn’t mean harmless. The infection represents a biologically active standoff between the host and the pathogen, with subtle shifts in the immune system reflecting that ongoing tension.4PubMed Central. Alterations in the Immune Response in Individuals with Latent Tuberculosis Infection If the immune system weakens, whether from HIV, malnutrition, aging, immunosuppressive medications, or other causes, those walled-off bacteria can reactivate. That is when TB becomes dangerous.
What Active TB Does to Your Lungs
When TB reactivates or progresses to active disease, the lungs bear the brunt. The bacteria multiply, and the immune system’s attempts to fight them off cause collateral destruction. Granulomas break down, creating cavities in the lung tissue. These cavities are essentially holes where functional tissue used to be, and they provide an oxygen-rich environment where the bacteria thrive and multiply further. The result is a vicious cycle of immune destruction and bacterial growth.
The classic symptoms of pulmonary TB, a persistent cough lasting weeks, chest pain, fatigue, night sweats, and weight loss, reflect this ongoing battle. Weight loss during TB is common and can be significant. A study of over 700 patients undergoing the intensive phase of TB treatment in South India found that nearly one in five lost weight even while on medication, with an average loss of about two kilograms among those affected. The loss was worse among men, people with diabetes, and those who drank alcohol.5PubMed Central. Predictors of weight loss during the intensive phase of tuberculosis treatment in patients with drug-susceptible pulmonary tuberculosis in South India In many parts of the world, TB was historically known as “consumption” because of the way it visibly wasted people away.
One of the most alarming symptoms is coughing up blood. About eight percent of people with pulmonary TB will experience this at some point, and the causes are varied. TB can erode into blood vessels, or it can leave behind structural damage like bronchiectasis (permanently widened airways prone to infection and bleeding) that causes problems years after the original disease. A case report described a woman who had massive, life-threatening bleeding episodes six years after her TB had been treated, caused by destroyed lung tissue and fungal balls that had colonized the cavities left behind.6PubMed Central. Post-primary pulmonary TB haemoptysis – When there is more than meets the eye
When TB Leaves the Lungs
TB is primarily a lung disease, but the bacteria can spread through the bloodstream or lymphatic system to virtually any organ. Extrapulmonary TB accounts for a meaningful share of all TB cases, and its diversity makes it one of the trickier forms to diagnose and treat. The disease can settle in the spine (known as Pott’s disease), the membranes surrounding the brain (tuberculous meningitis), the abdomen, the lymph nodes (historically called scrofula), and the urinary and reproductive systems.7PubMed Central. A Case of Pott’s Disease Complicated by Tuberculous Meningitis and Psoas Abscess Diagnosed by Computed Tomography-Guided Percutaneous Drainage
TB meningitis is among the most feared forms. It inflames the membranes around the brain and spinal cord, causing headaches, confusion, seizures, and, if not treated quickly, permanent neurological damage or death. Spinal TB can collapse vertebrae, leading to severe back deformity and even paralysis. These complications can occur alongside pulmonary TB or in isolation, which makes extrapulmonary TB especially dangerous in settings where doctors aren’t looking for it outside the lungs.
The overlap of multiple forms in a single patient illustrates just how aggressive disseminated TB can be. In the Pott’s disease case report above, for instance, the patient simultaneously had spinal destruction, meningitis, and a large abscess in the muscle beside the spine. Each of these alone would be serious. Together, they represent the kind of cascading damage TB can cause when the immune system fails to contain it.
The Damage That Stays After a Cure
Here is something that surprises many people: successfully completing TB treatment and being declared cured does not mean your lungs go back to normal. Post-tuberculosis lung disease is a recognized condition, and it is far more common than most people realize. Patients can be left with abnormal lung function, persistent cough, shortness of breath, and progressive changes visible on chest scans, even after the bacteria are gone.8Breathe. Post-tuberculosis lung disease A past history of pulmonary TB is an established risk factor for long-term respiratory impairment, yet this outcome often goes unrecognized despite being relatively common and significantly affecting quality of life.9PubMed Central. Tuberculosis and lung damage: from epidemiology to pathophysiology
A scoping review of long-term outcomes after TB found consistent evidence that the disease is linked to chronic airflow obstruction, reduced lung function, and an increased long-term risk of lung cancer. Younger adults appear more prone to developing chronic obstructive pulmonary disease after TB in high-burden settings, while older individuals face broader post-TB complications.10PubMed Central. Beyond Cure: A Scoping Review of Post-Tuberculosis Long-Term Health Outcomes The scarring, fibrosis, and structural remodeling left behind by the disease create a fundamentally different lung. For many TB survivors, the battle with breathing difficulties continues long after the infection itself is over.
This is a growing area of concern in global health because millions of people are cured of TB each year, and a large fraction of them are left with some degree of lung damage. The healthcare system tends to focus on getting patients through treatment and achieving microbiological cure, but the follow-up care for post-TB disability is sparse in most high-burden countries.
TB and HIV Together
The collision of TB and HIV is one of the worst synergies in infectious disease. HIV weakens the very immune cells that TB exploits, making progression from latent infection to active disease far more likely. TB, in turn, is the leading cause of hospitalization in people living with HIV worldwide. The mortality gap between co-infected and HIV-negative TB patients is stark: in 2023, roughly 24% of people who had both TB and HIV died, compared to about 11% of those with TB alone.11PubMed Central. Tuberculosis and HIV coinfection: Progress and challenges towards reducing incidence and mortality
A large study across 241 clinics in the Democratic Republic of Congo found that TB/HIV co-infection more than doubled the odds of death compared to TB alone, and it also roughly doubled the risk of patients being lost to follow-up, meaning they dropped out of care entirely.12PubMed Central. Risk Factors for TB/HIV Coinfection and Consequences for Patient Outcomes: Evidence from 241 Clinics in the Democratic Republic of Congo Co-infection also made it harder to suppress the HIV viral load, so the diseases compound each other in both directions. Sub-Saharan Africa, where both diseases are most prevalent, bears the heaviest burden of this overlap.
Diagnosing TB Is Harder Than You Might Think
If you picture TB diagnosis as a simple test, the reality is more complicated. The gold standard for confirming TB has traditionally been growing the bacteria from a patient’s sputum sample in a lab, but that takes weeks. A widely used rapid molecular test, GeneXpert, has transformed diagnosis by returning results within hours. For pulmonary TB, one evaluation found it had about 90% sensitivity and 87% specificity. But for extrapulmonary TB, where the bacteria may be in spinal fluid, tissue, or lymph nodes rather than sputum, performance drops, with sensitivity around 82% and specificity near 79%.13PubMed Central. Diagnostic utility of GeneXpert MTB/RIF assay versus conventional methods for diagnosis of pulmonary and extra-pulmonary tuberculosis Newer versions of the test have improved sensitivity further, though sometimes at the cost of specificity.14Scientific Reports. A Comparative Evaluation of the New Genexpert MTB/RIF Ultra and other Rapid Diagnostic Assays for Detecting Tuberculosis in Pulmonary and Extra Pulmonary Specimens
For specific sites like the spine, however, results can be excellent. One study of spinal TB found GeneXpert had about 96% sensitivity and 96% specificity on tissue samples, with results available within 48 hours compared to a median of 35 days for traditional cultures.15PubMed. GeneXpert polymerase chain reaction for spinal tuberculosis: an accurate and rapid diagnostic test Speed matters enormously here because spinal TB can cause irreversible damage if treatment is delayed.
Children pose a particular diagnostic challenge. Kids with TB often can’t produce the sputum samples that standard tests rely on, and the bacterial load in their samples tends to be low, making microbiological confirmation difficult. Optimizing clinical approaches, rather than relying solely on lab tests, is considered critical for closing detection gaps in childhood TB.16PubMed Central. Diagnostic Challenges in Childhood Pulmonary Tuberculosis-Optimizing the Clinical Approach Researchers are also exploring non-sputum-based diagnostics, including tests that use blood, urine, or stool samples, which are easier to collect from children and from people living with HIV who may also struggle to produce sputum.17PubMed Central. Non-sputum-based samples and biomarkers for detection of Mycobacterium tuberculosis: the hope to improve childhood and HIV-associated tuberculosis diagnosis Early-stage work has even explored biomarkers in exhaled breath condensate as a potential non-invasive detection method.18PubMed. MicroRNAs in exhaled breath Condensate: Novel non-invasive biomarkers for tuberculosis diagnosis
The Treatment Is Long and Rough
Standard drug-susceptible TB treatment lasts at least six months. The regimen involves multiple antibiotics taken simultaneously, and the side effects can be serious. First-line TB drugs are associated with liver toxicity, nerve damage in the hands and feet, joint pain, vision changes, and gastrointestinal problems. These adverse effects frequently lead to treatment interruptions and decreased adherence, which is a major concern because incomplete treatment breeds drug resistance.19PubMed Central. The Adverse Effects of Tuberculosis Treatment: A Comprehensive Literature Review
When the bacteria are resistant to first-line drugs, things get much worse. Drug-resistant TB requires longer treatment courses, sometimes lasting 18 months or more, using second-line medications that tend to be more toxic and less well tolerated. The extended duration, combined with worse side effects, makes adherence even harder.20Current Research in Microbial Sciences. Impacts of MDR/XDR-TB on the global tuberculosis epidemic: Challenges and opportunities Some second-line drugs can cause permanent hearing loss, severe psychiatric symptoms, or kidney damage. For patients with extensively drug-resistant TB, treatment options become very limited, and outcomes are considerably worse.
The Financial Devastation
TB doesn’t just attack the body. It attacks household finances. Even in countries that offer free TB treatment, patients still incur devastating costs from lost income, transportation to clinics, nutrition, and hospitalization. A systematic review found that total mean costs per person for TB care ranged from about $7 to over $11,000, with drug-resistant TB consistently costing more.21PubMed Central. The catastrophic cost of TB care: Understanding costs incurred by individuals undergoing TB care in low-, middle-, and high-income settings – A systematic review Hospitalization and lost income were the biggest drivers of these costs.
A national survey of TB-affected households in Tanzania put concrete numbers on the human toll. About 45% of all TB-affected households faced catastrophic costs, defined as costs exceeding a set threshold of household income or expenditure. Among households dealing with multidrug-resistant TB, that figure jumped to 80%. Income loss while accessing TB services and spending on nutritional supplements together accounted for roughly two-thirds of costs. Over half of patients borrowed money or sold assets to finance their treatment, and 86% reported that their financial situation had worsened because of TB.22PubMed Central. Economic burden of tuberculosis in Tanzania: a national survey of costs faced by tuberculosis-affected households The disease concentrates in poorer communities and then pushes those communities deeper into poverty.
Why the BCG Vaccine Isn’t Enough
Most people in high-burden countries receive the BCG vaccine as infants. It is over a century old and remains the only licensed TB vaccine. BCG does provide substantial protection against severe forms of childhood TB, particularly meningitis and disseminated disease in young children. But its effectiveness against pulmonary TB in adults, which is the form that drives most transmission and death, is inconsistent. Protection varies considerably across populations and geographic regions, and it wanes over time. Studies on BCG revaccination have shown some reduction in latent TB infection rates, particularly among high-risk groups like healthcare workers, but the protection against developing active TB disease has been modest and inconsistent.23PubMed Central. Bacillus Calmette-Guérin (BCG) Revaccination and Protection Against Tuberculosis: A Systematic Review
This gap between infant vaccination and adult disease is one reason TB has been so stubbornly difficult to eliminate. Several new vaccine candidates are in clinical trials, and some have shown promising results, but none have yet been approved for routine use. Until a more effective vaccine exists, TB control depends heavily on finding and treating active cases quickly and treating latent infections in high-risk individuals.
A Disease That Has Been With Us for 70,000 Years
Part of what makes TB so effective at exploiting human biology is the sheer length of time it has had to adapt. For decades, scientists assumed TB jumped to humans from cattle during the shift to farming and animal domestication. That narrative has been overturned by genetic evidence. Studies now show that the TB bacterium originated as a human pathogen in Africa and spread around the world alongside the migrations of modern humans out of the continent, potentially as far back as 70,000 years ago.24PubMed Central. The paleopathological evidence on the origins of human tuberculosis: a review The rise in TB during the Neolithic period was driven not by animal-to-human transmission but by growing human population density, which gave the airborne pathogen more opportunities to spread.
More recent lineages of TB expanded globally during waves of trade, exploration, and colonization, and genetic analyses have found that different TB lineages show an association with different human genetic backgrounds, suggesting a long co-evolutionary arms race between pathogen and host.25PubMed Central. Host-pathogen coevolution in human tuberculosis This deep history means TB is not a random invader. It is exquisitely tuned to human immune defenses, which partly explains why it can persist for decades in a latent state and why building effective immunity against it has proved so difficult.
New Treatment Strategies Beyond Antibiotics
Given the challenges of drug resistance and lengthy treatment courses, researchers are exploring a fundamentally different angle: instead of targeting the bacterium directly, modulate the patient’s own immune system to fight the infection more effectively. These host-directed therapies aim to boost the body’s natural defenses, reduce the immune-driven tissue destruction that causes so much of TB’s damage, and potentially shorten treatment duration. Early work has focused on promoting autophagy, a cellular recycling process that can help clear bacteria from inside infected cells, as well as stimulating the production of natural antimicrobial compounds.26PubMed Central. Host-directed therapy for tuberculosis
Some of the candidate drugs are already approved for other conditions, which could accelerate their path to clinical use for TB. The appeal is that host-directed approaches could work regardless of the bacterium’s drug-resistance profile, since they don’t target the pathogen directly. Cell culture and animal model studies have shown that modulating specific immune pathways can limit both infection and the tissue destruction that follows.27PubMed Central. Host-Directed Therapies for Tuberculosis These therapies are not expected to replace antibiotics but to work alongside them, potentially reducing the months of treatment and the lung damage that TB leaves behind. Clinical trials are still in relatively early stages, but this represents one of the more genuinely novel directions in TB treatment in decades.